Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database - PubMed (original) (raw)
Clinical Trial
Predicting the response to sumatriptan: the Sumatriptan Naratriptan Aggregate Patient Database
Hans Christoph-Diener et al. Neurology. 2004.
Abstract
Objective: The efficacy and tolerability profiles of sumatriptan and other 5HT(1B/1D) agonists (triptans) have been well established. However, the determinants for optimal response to sumatriptan are unknown. The Sumatriptan Naratriptan Aggregate Patient (SNAP) database contains data from 128 clinical trials including 28,407 migraine sufferers treating over 130,000 attacks. The authors analyzed these data to identify factors predicting response (headache relief and pain-free response) to sumatriptan.
Methods: The authors assessed 24 possible univariate predictors of headache response in 3,706 patients (18 years and older) receiving sumatriptan tablets 100 mg or placebo in a double-blind study using recursive partitioning and logistic regression techniques.
Results: The authors found seven predictors of headache relief 2 hours postdose. Moderate pain at baseline was the strongest predictor (adjusted p = 3.32 x 10(-35)), followed by absence of a disability requiring bedrest (adjusted p = 3.11 x 10(-18)). Other predictors included absence at baseline of vomiting, pulsating pain, nausea, or photophobia/phonophobia, and onset of headache during daytime hours. Logistic regression confirmed that treatment with sumatriptan was the strongest predictor of headache relief, with significant baseline covariates being pain severity, level of disability, and presence or absence of vomiting. A similar pattern of results was reported for predictors of pain-free response 2 hours after taking sumatriptan.
Conclusions: Pretreatment pain severity is the most important predicting factor for response to sumatriptan in migraine attacks: the lower baseline severity, the better.
Similar articles
- A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.
Winner P, Ricalde O, Le Force B, Saper J, Margul B. Winner P, et al. Arch Neurol. 1996 Feb;53(2):180-4. doi: 10.1001/archneur.1996.00550020092020. Arch Neurol. 1996. PMID: 8639069 Clinical Trial. - Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis.
Lipton RB, Pascual J, Goadsby PJ, Massiou H, McCarroll KA, Vandormael K, Jiang K, Lines CR. Lipton RB, et al. Headache. 2001 Sep;41(8):754-63. doi: 10.1046/j.1526-4610.2001.01139.x. Headache. 2001. PMID: 11576198 - Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials.
Winner P, Landy S, Richardson M, Ames M. Winner P, et al. Clin Ther. 2005 Nov;27(11):1785-94. doi: 10.1016/j.clinthera.2005.11.009. Clin Ther. 2005. PMID: 16368449 - Spotlight on almotriptan in migraine.
Keam SJ, Goa KL, Figgitt DP. Keam SJ, et al. CNS Drugs. 2002;16(7):501-7. doi: 10.2165/00023210-200216070-00006. CNS Drugs. 2002. PMID: 12056924 Review. - Sumatriptan: pharmacological basis and clinical results.
Dahlöf CG. Dahlöf CG. Curr Med Res Opin. 2001;17 Suppl 1:s35-45. doi: 10.1185/0300799039117010. Curr Med Res Opin. 2001. PMID: 12463276 Review.
Cited by
- Predictors of Triptan Response in Pediatric Migraine.
Johnson HF, Goadsby PJ, Gelfand AA. Johnson HF, et al. Pediatr Neurol. 2016 May;58:37-40. doi: 10.1016/j.pediatrneurol.2016.01.022. Epub 2016 Mar 8. Pediatr Neurol. 2016. PMID: 26968976 Free PMC article. - Factors associated with insufficient response to acute treatment of migraine in Japan: analysis of real-world data from the Adelphi Migraine Disease Specific Programme.
Hirata K, Ueda K, Ye W, Kim Y, Komori M, Jackson J, Cotton S, Rajan N, Treuer T. Hirata K, et al. BMC Neurol. 2020 Jul 8;20(1):274. doi: 10.1186/s12883-020-01848-4. BMC Neurol. 2020. PMID: 32641075 Free PMC article. - Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches.
Tepper SJ, Dodick DW, Schmidt PC, Kellerman DJ. Tepper SJ, et al. Headache. 2019 Apr;59(4):509-517. doi: 10.1111/head.13482. Epub 2019 Jan 30. Headache. 2019. PMID: 30698272 Free PMC article. Clinical Trial. - The Gut-brain Connection and Episodic Migraine: an Update.
Nguyen L, Hindiyeh N, Ray S, Vann RE, Aurora SK. Nguyen L, et al. Curr Pain Headache Rep. 2023 Nov;27(11):765-774. doi: 10.1007/s11916-023-01175-6. Epub 2023 Oct 4. Curr Pain Headache Rep. 2023. PMID: 37792173 Free PMC article. Review. - Patient Factors in the Dose Selection of Oral Sumatriptan for Acute Migraine: A Post Hoc Analysis of Two Randomized Controlled Studies.
Fisher M, Aher A, Araga M, Franks B. Fisher M, et al. Pain Ther. 2023 Jun;12(3):853-861. doi: 10.1007/s40122-023-00511-3. Epub 2023 Apr 27. Pain Ther. 2023. PMID: 37103731 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical